

# Daily Journal

SEPTEMBER 27, 2011

## TOP 100 LAWYERS IN CALIFORNIA

### EDITORS' NOTE

From the mortgage crisis to the Gulf oil spill to virtually every major intellectual property dispute, California lawyers are playing leading roles. But they don't just clean up big messes. They secure funding and regulatory approval for cutting-edge developments in water, energy, technology and biotechnology that are the promise of the future.

We aim for this list to be a kaleidoscope of the California legal scene. There are divorce attorneys and public finance lawyers, prosecutors and criminal defenders and much, much more.

We reviewed hundreds of nominations from members of the legal community and from our own editors and reporters to compile this list. It is never an easy task — the list isn't long enough — but it is fun. Read on. We know you'll enjoy learning about these people as much as we did.

— The Editors

## ROLLIN B. CHIPPEY II



### ROLLIN B. CHIPPEY II

Morgan Lewis  
San Francisco  
Practice type: Litigation  
Specialty: Real estate, commercial

core of the case, he compared the disease to the gradual closing of a 16-lane highway to one “where there is no traffic flowing.”

“There are ways to convey the information in an effective, understandable and somewhat dramatic way,” Chippey said.

Otherwise, he added, “You can get lost in the medicine, in the science of it, and not deliver the message you need to deliver.”

The jury found that defendants Actelion Ltd., a Swiss bio-pharmaceutical firm, and associated defendants, had interfered with

**E**xplaining to a jury the complexities involved in a high-stakes pharmaceutical case isn't easy, but Chippey was able to bring it home, winning a \$516 million judgment for client Asahi Kasei Pharma Corp.

Key, Chippey said, was his ability to communicate difficult medical terms in a jury-friendly way. In describing pulmonary arterial hypertension, for instance, which was at the

a 2006 license agreement, quashing Asahi Kasei Pharma Corp.'s development of a promising new drug that would have treated such potentially deadly ailments as pulmonary arterial hypertension. *Asahi Kasei Pharma Corp. v. Actelion Ltd.*, CIV 478533 (San Mateo Super. Ct., filed Nov. 19, 2008).

Chippey showed that the defendants' motive was to keep the market free for Actelion's own drug Tracleer.

— Pat Broderick